The effects of lipid-lowering therapy on graft patency in coronary bypass surgery patients

Heart Surgery Forum

Volumn 9, Issue 3, 2006, Pages 150-153

  Sungun, Mutasum ^a   Hulusi, Melih ^a   Ulusoy, Rifat Eralp ^a   Keskin, Ozcan ^a   Pocan, Sibel ^a   Inan, Kaan ^a   Yilmaz, Ahmet Turan ^a  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANGIOCARDIOGRAPHY; ARTERY GRAFT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY CIRCUMFLEX BRANCH; DISEASE FREE INTERVAL; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAFT PATENCY; GRAFT SURVIVAL; HEART MUSCLE ISCHEMIA; HUMAN; INTERNAL MAMMARY ARTERY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYOPATHY; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; RIGHT CORONARY ARTERY; RISK REDUCTION; SAPHENOUS VEIN; SURVIVAL TIME; TREATMENT RESPONSE; VEIN GRAFT; ADULT; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; HYPERLIPIDEMIA; INCIDENCE; METHODOLOGY; MIDDLE AGED; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; TURKEY (REPUBLIC); VASCULAR PATENCY;

ADULT; ANTILIPEMIC AGENTS; COMORBIDITY; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; FEMALE; GRAFT SURVIVAL; HUMANS; HYPERLIPIDEMIAS; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; TURKEY; VASCULAR PATENCY;

EID: 33751362651     PISSN: 10983511     EISSN: None     Source Type: Journal    
DOI: 10.1532/HSF98.20051158     Document Type: Article

References (28)

1. American Heart Association. 2003. Statistical fact sheet populations. International Disease Statistics. Dallas, Tex: American Heart Association.
2. Azen SP, Mack WJ, Cashin-Hemphill L, et al. 1996. Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation 93:34-41.
3. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. 1987. Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257:3233-40.
4. Brown G, Albers JJ, Fisher LD, et al. 1990. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 323:1289-98.
5. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. 1990. Beneficial effects of colestipol-niacin therapy on coronary atherosclerosis. A 4-year follow-up. JAMA 264:3013-7.
6. Crouse JR 3rd, Byington RP, Bond MG, et al. 1995. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 75:455-9.
7. Frick MH, Syvanne M, Nieminen NS, et al. 1997. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 96:2137-43.
8. Friedewald WT, Levy RI, Fredrickson DS. 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502.
9. Haim M, Benderly M, Brunner D, et al. 1999. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention Registry. Circulation 100:475-82.
10. Heart Protection Study Collaborative Group. 2002. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22.
11. Huttunen J, Manninen V, Manttari M, et al. 1991. The Helsinki Heart Study: central findings and clinical implications. Ann Med 23:155-9.
12. Jukema JW, Bruschke AVG, Boven JV, et al. 1995. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 91:2528-40.
13. Lewis SJ, Moye LA, Sacks FM, et al. 1998. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 129:681-9.
14. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. 1998. Prevention of cardiovascular events and death in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-157.
15. The Post Coronary Artery Bypass Graft (PCABG) Trial Investigators. 1997. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary artery bypass grafts. N Engl J Med 336:153-62.
16. Pedersen TR, Kjekshus J, Faergeman O, et al. 1998. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 97:1453-60.
17. Pitt B, Ellis SG, Mancini GB, Rosman HS, McGovern ME. 1993. Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I). Am J Cardiol 72:31-5.
18. Pitt B, Mancini GB, Ellis SG, Rosman HS, Park JS, McGovern ME. 1995. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC 1): reduction in atherosclerosis progression and clinical events. PLAC 1 investigation. J Am Coll Cardiol 26:1133-9.
19. Ravnskov U. 1992. Cholesterol-lowering trials in coronary heart disease: frequency of citation and outcome. BMJ 305:15-9.
20. Rubins HB, Robins SJ, Collins D, et al. 1999. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341:410-8.
21. Sacks FM, Moye LA, Davis BR, et al. 1998. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial. Circulation 97:1446-52.
22. Scandinavian Simvastatin Survival Study Group. 1994. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-9.
23. Sever PS, Dahlof P, Poulter NR, et al. 2003. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149-58.
24. Shepherd J, Blauw GJ, Murphy MB, et al. 2002. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancer 360:1623-30.
25. Shepherd J, Cobbe SM, Ford I, et al. 1995. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Group (WOSCOPS). N Engl J Med 333:1301-7.
26. WHO. 1980. Cooperative trial on primary prevention of ischemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators. Lancet 2:379-85.
27. WHO, The World Health Report 2002. Reducing Risks, Promoting Healthy Life. Geneva: World Health Organization.
28. West of Scotland Coronary Prevention Study (WOSCOPS) Group. 1998. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study. Circulation 97:1440-5.